

| | | |
|--------------|--|-------------|
| AD-A152 230 | EMERGENCY AND CONTINUOUS EXPOSURE LIMITS FOR SELECTED AIRBORNE CONTAMINAN. (U) NATIONAL RESEARCH COUNCIL WASHINGTON DC COMMITTEE ON TOXICOLO. OCT 84 | 1/1 |
| UNCLASSIFIED | DAND17-83-C-3028 | F/G 6/20 NL |

EMERGENCY AND CONTINUOUS EXPOSURE LIMITS FOR SELECTED
AIRBORNE CONTAMINAN. (U) NATIONAL RESEARCH COUNCIL
WASHINGTON DC COMMITTEE ON TOXICOLO. OCT 84
DAMD17-83-C-3028 F/G 6/20

1/1

UNCLASSIFIED


F/G 6/28

HI

END

12 MED

PTIC



MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS-1963-A

CRZ

AD-A152 230

Emergency and Continuous Exposure Limits for Selected Airborne Contaminants

Volume 3
Bromotrifluoromethane

Contract DAMD-17-82-C-3028

DTIC FILE COPY

DTIC
ELECTE
APR 9 1985
S A D

This document has been approved
for public release and sale; its
distribution is unlimited.

85

4 2

069

DO NOT PRINT THESE INSTRUCTIONS AS A PAGE IN A REPORT

INSTRUCTIONS

Optional Form 272, Report Documentation Page is based on Guidelines for Format and Production of Scientific and Technical Reports, ANSI Z39.18-1974 available from American National Standards Institute, 1430 Broadway, New York, New York 10018. Each separately bound report—for example, each volume in a multivolume set—shall have its unique Report Documentation Page.

1. Report Number. Each individually bound report shall carry a unique alphanumeric designation assigned by the performing organization or provided by the sponsoring organization in accordance with American National Standard ANSI Z39.23-1974, Technical Report Number (STRN). For registration of report code, contact NTIS Report Number Clearinghouse, Springfield, VA 22161. Use uppercase letters, Arabic numerals, slashes, and hyphens only, as in the following examples: FASEB/NS-75/87 and FAA/RD-75/09.
2. Leave blank.
3. Recipient's Accession Number. Reserved for use by each report recipient.
4. Title and Subtitle. Title should indicate clearly and briefly the subject coverage of the report, subordinate subtitle to the main title. When a report is prepared in more than one volume, repeat the primary title, add volume number and include subtitle for the specific volume.
5. Report Date. Each report shall carry a date indicating at least month and year. Indicate the basis on which it was selected (e.g., date of issue, date of approval, date of preparation, date published).
6. Sponsoring Agency Code. Leave blank.
7. Author(s). Give name(s) in conventional order (e.g., John R. Doe, or J. Robert Doe). List author's affiliation if it differs from the performing organization.
8. Performing Organization Report Number. Insert if performing organization wishes to assign this number.
9. Performing Organization Name and Mailing Address. Give name, street, city, state, and ZIP code. List no more than two levels of an organizational hierarchy. Display the name of the organization exactly as it should appear in Government indexes such as Government Reports Announcements & Index (GRA & I).
10. Project/Task/Work Unit Number. Use the project, task and work unit numbers under which the report was prepared.
11. Contract/Grant Number. Insert contract or grant number under which report was prepared.
12. Sponsoring Agency Name and Mailing Address. Include ZIP code. Cite main sponsors.
13. Type of Report and Period Covered. State interim, final, etc., and, if applicable, inclusive dates.
14. Performing Organization Code. Leave blank.
15. Supplementary Notes. Enter information not included elsewhere but useful, such as: Prepared in cooperation with . . . Translation of . . . Presented at conference of . . . To be published in . . . When a report is revised, include a statement whether the new report supersedes or supplements the older report.
16. Abstract. Include a brief (200 words or less) factual summary of the most significant information contained in the report. If the report contains a significant bibliography or literature survey, mention it here.
17. Document Analysis. (a). Descriptors. Select from the Thesaurus of Engineering and Scientific Terms the proper authorized terms that identify the major concept of the research and are sufficiently specific and precise to be used as index entries for cataloging.
(b). Identifiers and Open-Ended Terms. Use identifiers for project names, code names, equipment designators, etc. Use open-ended terms written in descriptor form for those subjects for which no descriptor exists.
(c). COSATI Field/Group. Field and Group assignments are to be taken from the 1964 COSATI Subject Category List. Since the majority of documents are multidisciplinary in nature, the primary Field/Group assignment(s) will be the specific discipline, area of human endeavor, or type of physical object. The application(s) will be cross-referenced with secondary Field/Group assignments that will follow the primary posting(s).
18. Distribution Statement. Denote public releasability, for example "Release unlimited", or limitation for reasons other than security. Cite any availability to the public, with address, order number and price, if known.
19. & 20. Security Classification. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED).
21. Number of pages. Insert the total number of pages, including introductory pages, but excluding distribution list, if any.
22. Price. Enter price in paper copy (PC) and/or microfiche (MF) if known.

| | | | |
|---|----------------------|--|-------------------------------------|
| REPORT DOCUMENTATION PAGE | 1. REPORT NO. | 2. | 3. Recipient's Accession No. |
| | | 4D-4152 | D30 |
| 4. Title and Subtitle | | 5. Report Date | |
| Emergency and Continuous Exposure Limits for Selected Airborne Contaminants. Volume 3. Bromotrifluoromethane. | | October 1984 | |
| 7. Author(s) | | 6. | |
| | | | |
| 9. Performing Organization Name and Address | | 8. Performing Organization Rept. No. | |
| National Research Council Commission on Life Sciences 2101 Constitution Ave., NW Washington, DC 20418 | | | |
| 12. Sponsoring Organization Name and Address | | 10. Project/Task/Work Unit No. | |
| Office of Naval Research | | | |
| | | 11. Contract(C) or Grant(G) No. | |
| | | (C) N00017 C-0049 (G) | |
| | | 13. Type of Report & Period Covered | |
| | | Final | |
| 15. Supplementary Notes | | 14. | |
| | | | |
| 16. Abstract (Limit: 200 words) | | | |
| <p>This report contains information on the physical, chemical, and toxicologic properties of CBrF₃, a fire extinguishing chemical. It also contains emergency exposure limits (EELs) for 30 min and 1 hr, and contains exposure limits for 90 days. Toxicologic data include: Effects of CBrF₃ on the Central Nervous System, Effects of CBrF₃ on the Respiratory System, Effects of CBrF₃ on the Cardiovascular System, Effects of CBrF₃ on the Hematopoietic System, Effects of CBrF₃ on the Reproductive System, and Effects of CBrF₃ on the Immune System.</p> | | | |
| 17. Document Analysis a. Descriptors | | | |
| Bromotrifluoromethane, CBrF ₃ , fire extinguishing chemical. | | | |
| b. Identifiers/Open-Ended Terms | | | |
| | | | |
| c. COSATI Field/Group | | | |
| | | | |
| 18. Availability Statement: | | 19. Security Class (This Report) | 21. No. of Pages |
| distribution is unlimited. | | Unclassified | 27 |
| | | 20. Security Class (This Page) | 22. Price |
| | | Unclassified | |

EMERGENCY AND CONTINUOUS EXPOSURE LIMITS
FOR SELECTED AIRBORNE CONTAMINANTS

Volume 3 - BROMOTRIFLUOROMETHANE

COMMITTEE ON TOXICOLOGY

Board on Toxicology and Environmental Health Hazards
Commission on Life Sciences
National Research Council

Contract DAMD-17-82-C-3028

National Academy Press
Washington, D.C.
October 1984



1

| | |
|-----|--|
| For | <input checked="checked" type="checkbox"/> |
| 1 | <input type="checkbox"/> |
| 2 | <input type="checkbox"/> |
| 3 | <input type="checkbox"/> |
| 4 | <input type="checkbox"/> |
| 5 | <input type="checkbox"/> |
| 6 | <input type="checkbox"/> |
| 7 | <input type="checkbox"/> |
| 8 | <input type="checkbox"/> |
| 9 | <input type="checkbox"/> |
| 10 | <input type="checkbox"/> |
| 11 | <input type="checkbox"/> |
| 12 | <input type="checkbox"/> |
| 13 | <input type="checkbox"/> |
| 14 | <input type="checkbox"/> |
| 15 | <input type="checkbox"/> |
| 16 | <input type="checkbox"/> |
| 17 | <input type="checkbox"/> |
| 18 | <input type="checkbox"/> |
| 19 | <input type="checkbox"/> |
| 20 | <input type="checkbox"/> |
| 21 | <input type="checkbox"/> |
| 22 | <input type="checkbox"/> |
| 23 | <input type="checkbox"/> |
| 24 | <input type="checkbox"/> |
| 25 | <input type="checkbox"/> |
| 26 | <input type="checkbox"/> |
| 27 | <input type="checkbox"/> |
| 28 | <input type="checkbox"/> |
| 29 | <input type="checkbox"/> |
| 30 | <input type="checkbox"/> |
| 31 | <input type="checkbox"/> |
| 32 | <input type="checkbox"/> |
| 33 | <input type="checkbox"/> |
| 34 | <input type="checkbox"/> |
| 35 | <input type="checkbox"/> |
| 36 | <input type="checkbox"/> |
| 37 | <input type="checkbox"/> |
| 38 | <input type="checkbox"/> |
| 39 | <input type="checkbox"/> |
| 40 | <input type="checkbox"/> |
| 41 | <input type="checkbox"/> |
| 42 | <input type="checkbox"/> |
| 43 | <input type="checkbox"/> |
| 44 | <input type="checkbox"/> |
| 45 | <input type="checkbox"/> |
| 46 | <input type="checkbox"/> |
| 47 | <input type="checkbox"/> |
| 48 | <input type="checkbox"/> |
| 49 | <input type="checkbox"/> |
| 50 | <input type="checkbox"/> |
| 51 | <input type="checkbox"/> |
| 52 | <input type="checkbox"/> |
| 53 | <input type="checkbox"/> |
| 54 | <input type="checkbox"/> |
| 55 | <input type="checkbox"/> |
| 56 | <input type="checkbox"/> |
| 57 | <input type="checkbox"/> |
| 58 | <input type="checkbox"/> |
| 59 | <input type="checkbox"/> |
| 60 | <input type="checkbox"/> |
| 61 | <input type="checkbox"/> |
| 62 | <input type="checkbox"/> |
| 63 | <input type="checkbox"/> |
| 64 | <input type="checkbox"/> |
| 65 | <input type="checkbox"/> |
| 66 | <input type="checkbox"/> |
| 67 | <input type="checkbox"/> |
| 68 | <input type="checkbox"/> |
| 69 | <input type="checkbox"/> |
| 70 | <input type="checkbox"/> |
| 71 | <input type="checkbox"/> |
| 72 | <input type="checkbox"/> |
| 73 | <input type="checkbox"/> |
| 74 | <input type="checkbox"/> |
| 75 | <input type="checkbox"/> |
| 76 | <input type="checkbox"/> |
| 77 | <input type="checkbox"/> |
| 78 | <input type="checkbox"/> |
| 79 | <input type="checkbox"/> |
| 80 | <input type="checkbox"/> |
| 81 | <input type="checkbox"/> |
| 82 | <input type="checkbox"/> |
| 83 | <input type="checkbox"/> |
| 84 | <input type="checkbox"/> |
| 85 | <input type="checkbox"/> |
| 86 | <input type="checkbox"/> |
| 87 | <input type="checkbox"/> |
| 88 | <input type="checkbox"/> |
| 89 | <input type="checkbox"/> |
| 90 | <input type="checkbox"/> |
| 91 | <input type="checkbox"/> |
| 92 | <input type="checkbox"/> |
| 93 | <input type="checkbox"/> |
| 94 | <input type="checkbox"/> |
| 95 | <input type="checkbox"/> |
| 96 | <input type="checkbox"/> |
| 97 | <input type="checkbox"/> |
| 98 | <input type="checkbox"/> |
| 99 | <input type="checkbox"/> |
| 100 | <input type="checkbox"/> |

101

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.

This report has been reviewed by a group other than the authors according to procedures approved by a Report Review Committee consisting of members of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

The National Research Council was established by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy's purposes of furthering knowledge and of advising the federal government. The Council operates in accordance with general policies determined by the Academy under the authority of its Congressional charter of 1863, which establishes the Academy as a private, nonprofit, self-governing membership corporation. The Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in the conduct of their services to the government, the public, and the scientific and engineering communities. It is administered jointly by both Academies and the Institute of Medicine. The National Academy of Engineering and the Institute of Medicine were established in 1964 and 1970, respectively, under the charter of the National Academy of Sciences.

This study was prepared under Contract ~~N00017-C-0049~~ between the National Academy of Sciences and the Office of Naval Research.

Limited number of copies available from:

Committee on Toxicology
Board on Toxicology and Environmental
Health Hazards
National Research Council
2101 Constitution Avenue, N.W.
Washington, D.C. 20418

COMMITTEE ON TOXICOLOGY

Roger O. McClellan, Lovelace Inhalation Toxicology Research Institute,
Albuquerque, New Mexico, Chairman
Rose Dagirmanjian, University of Louisville, Louisville, Kentucky
David W. Gaylor, National Center for Toxicological Research,
Jefferson, Arkansas
Richard Griesemer, Oak Ridge National Laboratory, Oak Ridge, Tennessee
William Halperin, National Institute for Occupational Safety and Health,
Cincinnati, Ohio
Clark W. Heath, Jr., Emory University School of Medicine, Atlanta, Georgia
Meryl Karol, Graduate School of Public Health, Pittsburgh, Pennsylvania
Ronald J. Spangford, SRI International, Menlo Park, California
Thomas R. Tephly, The University of Iowa, Iowa City, Iowa
Lloyd B. Tepper, Air Products and Chemicals, Inc., Allentown, Pennsylvania
Clarence J. Terhaar, Eastman Kodak Company, Rochester, New York

National Research Council Staff

Francis N. Marzulli, Project Director
Kulbir S. Bakshi, Staff Officer
Norman Grossblatt, Editor
Beulah S. Bresler, Administrative Secretary

BOARD ON TOXICOLOGY AND ENVIRONMENTAL HEALTH HAZARDS

Gerald N. Wogan, Massachusetts Institute of Technology, Cambridge,
Massachusetts, Chairman
Donald Hornig, Harvard University, Boston, Massachusetts,
Co-Vice-Chairman
Philip Landrigan, National Institute for Occupational Safety and
Health, Cincinnati, Ohio, Co-Vice-Chairman
John Doull, University of Kansas Medical Center, Kansas City, Kansas
Herman N. Eisen, Massachusetts Institute of Technology, Cambridge,
Massachusetts
Emmanuel Farber, University of Toronto, Toronto, Ontario, Canada
David G. Hoel, National Institute of Environmental Health Sciences,
Research Triangle Park, North Carolina
Richard Merrill, University of Virginia Law School, Charlottesville,
Virginia
Vaun A. Newill, Exxon Corporation, New York, New York
Emil Pfitzer, Hoffmann-La Roche Inc., Nutley, New Jersey
Joseph V. Rodricks, Environ Corporation, Washington, D. C.
Liane B. Russell, Oak Ridge National Laboratory, Oak Ridge, Tennessee
Ellen Silbergeld, Environmental Defense Fund, Washington, D. C.
Peter Spencer, Albert Einstein College of Medicine, Bronx, New York

National Research Council Staff

Devra Lee Davis, Executive Director

ACKNOWLEDGMENTS

We acknowledge with thanks the assistance of the following previous committee members in the preparation of this report: Richard Bates, Health Effects Institute; Donald J. Ecobichon, McGill University; Howard I. Maibach, University of California, San Francisco; Robert Menzer, University of Maryland; Charles F. Reinhardt, E.I. duPont de Nemours and Company; Robert Snyder, Rutgers University; and Peter Spencer, Albert Einstein College of Medicine.

INTRODUCTION

The National Research Council's Committee on Toxicology recommends emergency exposure limits (EELs), short-term public limits (STPLs), and short-term public emergency limits (SPELs--formerly called public emergency limits or PELs) for a variety of chemicals of concern to its sponsoring agencies. The definitions and applicability of these limits and the criteria used to establish them were originally outlined in two documents prepared by the Committee (NRC, 1964, 1971a). In a revision of those documents (NRC, 1979a), the Committee summarized the principles used to establish exposure limits for short durations. The Committee has also recommended continuous exposure limits (CELs) in response to specific sponsor requests.

This document is one in a series prepared by the Committee that form the basis of the recommendations for EELs and CELs for selected chemicals. Since the Committee began recommending EELs and CELs for its military sponsors (U.S. Army, Navy, and Air Force), the scope of its recommendations has been expanded in response to a request by the National Aeronautics and Space Administration. The CELs, in particular, grew out of a Navy request for exposure limits for atmospheric contaminants in submarines. The EELs and CELs have been used as design criteria by the sponsors in considering the suitability of materials for particular missions (as in a submarine or a spacecraft) and in assessing the habitability of particular enclosed environments. They are recommended for narrowly defined occupational groups and are not intended for application in general industrial settings or as exposure limits for the general public.

The EEL is defined as a ceiling limit for an unpredictable single exposure, usually lasting 60 min or less, and never more than 24 h--an occurrence expected to be rare in the lifetime of any person. It reflects an acceptance of the statistical likelihood of the occurrence of a nonincapacitating, reversible effect in an exposed population. It is designed to avoid substantial decrements in performance during emergencies and might contain no uncertainty factor. The use of uncertainty factors will depend on the specific compound in question and on the type of effect produced by the compound.

The CEL is recommended in specific situations in which there may be exposure to a chemical continuously for up to 90 d. It is defined as a ceiling limit designed to avoid adverse health effects, either immediate or delayed, and to avoid degradation in crew performance that might endanger the objectives of a particular mission. Because data on continuous exposures are rarely available, uncertainty factors might be used, depending on the judgment of the Committee.

BACKGROUND INFORMATION

The Department of the Navy has requested a review of the toxicology of bromotrifluoromethane (CBrF₃) with recommendations for EELs and a 90-d CEL. Because CBrF₃ is used for firefighting aboard ships and might be used in submarines, the Navy is concerned about possible adverse health effects of its pyrolysis products.

PHYSICAL AND CHEMICAL PROPERTIES

Chemical formula: CBrF₃
Molecular weight: 148.9
Common name: Halon 1301
Synonyms: Freon 13BI, FC-13BI, Freon 1301
CAS number: 75-63-8
Boiling point: -57.8°C
Freezing point: -168°C
Vapor pressure: 10,868 mm Hg (20°C)
Solubility in water: 300 ppm (25°C)
Density, liquid: 1.57 g/ml (21°C)
General characteristics: Colorless, nonflammable, liquefied compressed gas with high density and low viscosity
Conversion factors: 1 ppm = 6.1 mg/m³
1 mg/m³ = 0.16 ppm

USES

CBrF₃ is used for extinguishing class A fires (of cellulosic materials, such as wood and paper), class B fires (of flammable fluids), and class C fires (of electric and electronic equipment). Most fires are extinguished in 5-10 s when the concentration of CBrF₃ in air is 5-7%. However, this concentration is maintained for about 10 min to avoid possible reignition. CBrF₃, however, is not effective in preventing the combustion or reaction of chemicals capable of oxidation without air such as cellulose nitrate and gunpowder; reactive metals such as sodium, potassium, and titanium; metal hydrides; and chemicals capable of autothermal decomposition such as organic peroxides and hydrazine (DuPont Company, undated).

On a weight basis, CBrF_3 is one of the more effective gaseous fire-extinguishing agents. It is up to 3 times more effective than carbon dioxide, about as effective as sodium-base dry powder, and somewhat less effective than potassium-base powder (DuPont Company, undated). CBrF_3 is preferred in extinguishing fires, because it causes minimal damage to equipment. The U.S. Navy has used CBrF_3 for shipboard firefighting and has considered its use in submarines (Farrier, 1983). However, it is unlikely to be used in submarines until ventilation problems involving removal of its pyrolysis products have been worked out.

SUMMARY OF TOXICITY INFORMATION

Several reviews have been published on the health effects of CBrF_3 (National Academy of Sciences, 1972; Haskell Laboratory, 1978; Van Stee, 1974).

EFFECTS ON HUMANS

No studies were found that examined the effects on humans of long-term exposures to CBrF_3 at low concentrations. The effects of acute exposure are summarized in Table 1.

Three subjects exposed at 7.1% were able to detect the odor of CBrF_3 and experienced mild ear, nose, and throat discomfort after 28 min of exposure (Stewart *et al.*, 1978). Slight to moderate irritation of the eyes and nose and pulmonary discomfort were reported at 10% and to a lesser degree in a person exposed at 5% (Hine *et al.*, 1968). No effects on pulmonary function have been observed.

As in studies on acute exposures of animals, the primary effects observed were cardiovascular and CNS effects. Humans exposed for 20 min at concentrations of 10% and greater had increased heart rates and a flattening of the T wave of the electrocardiogram (ECG). Cardiac arrhythmia was reported in one person who was exposed to CBrF_3 at 13% for 5 min (Hine *et al.*, 1968). Normal sinus rhythm was restored within 2 min after exposure ended. No ECG changes were observed in persons exposed to CBrF_3 at less than 10%.

Short (30-min) exposures of three healthy men at 0.1, 4.3, 4.5, and 7.1% produced CNS effects of varied degree, such as paresthesia, light-headedness, disturbances in balance, dizziness, and euphoria. All three were able to depart safely from a well-lighted exposure chamber (Stewart *et al.*, 1978).

Harrison *et al.* (1982) exposed six healthy military volunteers to 7% CBrF_3 for 3 h. The same volunteers were exposed on other days to sulfur hexafluoride, a placebo gas. Blood Halon concentrations were monitored to measure uptake. Each subject was given a battery of mental-performance tests to measure psychomotor, perceptual, and cognitive function. Vestibular function was examined by a balance-

TABLE 1

Effects on Humans of Short-Term Exposure to CRF3

| CRF3 Conc., % in air | Exposure Duration | Cardiovascular Effects | Central Nervous System Effects | Reference |
|----------------------------|----------------------|---|--|----------------------------|
| 10-17 | 15-25 min | Flattening of T wave, premature ventricular contractions, tachycardia | Paresthesia, light-headedness, buzzing in ears, numbness, confusion, fear of impending unconsciousness at concentrations above 14% | Hine et al., 1968 |
| 12-15 | 1 min | Increased heart rate, depressed T wave | Paresthesia, severe dizziness, fear of impending unconsciousness | Reinhardt and Reinke, 1972 |
| 10 | 20-25 min -- | -- | Drowsiness, light-headedness, decreases in judgment, alertness, neuromuscular skill | Hine et al., 1968 |
| 10 | 3-3.5 min | No ECG changes | Light-headedness, disturbances in balance and ability to respond to visual stimulus | Reinhardt and Reinke, 1972 |
| 10 | 1 min | Increased heart rate and blood pressure, depressed T wave | Slight paresthesia, dizziness | Reinhardt and Reinke, 1972 |
| 9 | 2 min | Increased heart rate, no ECG changes | Dizziness | Reinhardt and Reinke, 1972 |
| 7.1 | 30 min | No changes in ECG, blood pressure, or heart rate | Dizziness, light-headedness, euphoria; disturbances in equilibrium and coordination; increased EEG activity | Stewart et al., 1978 |
| 7 | 3 h | No changes in cardiac function | Decrement in mental performance tests | Harrison et al., 1982 |
| 7 | 3-3.5 min | No ECG changes | Light-headedness, disturbance in balance and ability to respond to visual stimulus | Reinhardt and Reinke, 1972 |
| 7 | 3 min | No ECG changes | Dizziness, faintness, or drowsiness in 6 of 8 men; increased reaction time; no effect on maze tracking tests | Call, 1973 |
| 6 | 3 min | Increased heart rate | Slight paresthesia, dizziness | Reinhardt and Reinke, 1972 |

Table 1 (continued)

| CBRF3 Conc., % in Air | Exposure Duration | Cardiovascular Effects | Central Nervous System Effects | Reference |
|-----------------------------|----------------------|---|---|-------------------------------|
| 5 | 20-25 min | No ECG changes | Drowsiness, light-headedness, slight effect on judgment | Hine et al., 1968 |
| 5 | 3-3.5 min | No ECG changes | None observed | Reinhardt and Reinke, 1972 |
| 4.3-4.5 | 30 min | No changes in ECG, blood pressure, or heart rate | Dizziness, light-headedness, euphoria, disturbances in equilibrium and coordination | Stewart et al., 1978 |
| 4 | 3 min | No ECG changes | Dizziness, faintness, or drowsiness in 3 of 8 men; increased reaction time; no effect on maze tracking tests | Call, 1973 |
| 3 | 3-3.5 min | No ECG changes | None observed | Reinhardt and Reinke, 1972 |
| 1 | 3-3.5 min | No ECG changes | None observed | Reinhardt and Reinke, 1972 |
| 0.1% | 30 min | No changes in ECG, blood pressure, or heart rate | None observed | Stewart et al., 1978 |

board test. The authors stated that no changes in hepatic function, cardiac function according to ECG, or vestibular function could be correlated with exposure to 7% CBrF₃ for 3 h. They also reported significant decrements in each mental-function test during the exposure period. These ranged from 11% to 17% mean reduction in function in the individual tests. Mental performance returned to normal within 0.5 h after exposure stopped. The authors reported that the extent of decreased mental performance was roughly comparable with that on waking at 3-5 a.m. or that associated with a blood alcohol concentration of 90 mg/100 ml (Harrison et al., 1982).

EFFECTS ON ANIMALS

The effects of short-term and prolonged exposures of animals to CBrF₃ are summarized in Tables 2 and 3, respectively. CBrF₃ is only slightly toxic in acute exposures. Underwriter's Laboratories, Inc., classified CBrF₃ among the least toxic fluorocarbons (Reinhardt and Reinke, 1972). A 2-h exposure at 85% in air was lethal to mice and guinea pigs (Paulet, 1962), and a 15-min exposure at 83.2% in air was lethal to rats (Reinhardt and Reinke, 1972). Oxygen deficiency was very likely a contributory cause of death in these cases. Clark and Tinston (1982) reported that a 10-min LC₅₀ of CBrF₃ mixed with oxygen was above 80% in rats. Mice, rats, guinea pigs, and rabbits all survived 2-h exposures to CBrF₃ at 50-80% mixed with 20% oxygen (Paulet, 1962). Longer exposures to CBrF₃ have reportedly resulted in deaths at lower concentrations (Haskell Laboratory, 1978). When one cat, six guinea pigs, four rabbits, ten mice, and ten rats were exposed at 37% for 7 h, all the animals except two mice and six rats died. The lowest reported concentration of CBrF₃ resulting in fatalities was 18%; one of four rabbits exposed for 7 h died (Haskell Laboratory, 1978).

Cardiovascular and CNS effects of exposures to CBrF₃ are discussed below.

CENTRAL NERVOUS SYSTEM EFFECTS

In addition to observation of gross behavioral changes in test animals, CNS effects have been studied by measuring changes in electroencephalograms (EEGs) and by using behavioral tests. In monkeys exposed to CBrF₃ at 70-80%, increased activation of EEGs coincided with an auditory or visual stimulus (Van Stee et al., 1970). Monkeys exposed at 20-50% had decrements in continuous and discrete avoidance-performance tests, and higher concentrations caused some animals to cease performance entirely, although there were no signs of general CNS depression or analgesia (Carter et al., 1970). CBrF₃ at 10.5-20% did not impair performance during the tests. In general, CNS effects have not been observed in animals exposed for less than 7 h to CBrF₃ at concentrations below 20%. Clark and

TABLE 2

Effects on Animals of Short-Term Exposure to CBrF₃

| CBrF ₃ Conc., % | Exposure Duration | Animal | Cardiovascular Effects | Central Nervous System Effects | Other Observations | Reference |
|-------------------------------|----------------------|--------------------------------------|--|--|--|-------------------------------|
| 85 ^a | 2 h | Mouse, guinea pig | -- | -- | Approximate lethal concentration | Paulet, 1962 |
| 83.2 ^b | 15 min | Rat | -- | -- | Approximate lethal concentration | Reinhardt and Reinke, 1972 |
| 42 ^b | 10 min | Rat | Ventricular tachycardia | Tremors, ataxia | -- | Clark and Tinston, 1982 |
| 81 ^a | 2 h | Rat, guinea pig | -- | Depression | -- | Paulet, 1962 |
| | Mouse | -- | Hyperactivity | -- | Paulet, 1962 | |
| | | Rabbit | -- | Convulsions, depression | -- | Paulet, 1962 |
| 80 ^c | Up to 40 min | Dog | Spontaneous arrhythmias, cardiac arrest and ventri- cular fibrillation after iv injection of epinephrine, decreased blood pressure | Agitation, convulsions | -- | Van Stee and Back, 1969 |
| 70-80 ^c | Up to 60 min | Monkey | -- | Activation of EKG, par- ticularly in presence of sensory stimuli | Suggested that CBrF ₃ affects "higher" CNS functions to greater degree than "lower" functions | Van Stee et al., 1970 |
| 20-80 ^c | 10-60 min | Monkey, baboon | Arrhythmias induced within 5-40 s, increased heart rate | Cortical depression | Epinephrine had less pressor effect than in dog | Van Stee and Back, 1969 |
| 60 ^a | 2 h | Rat, guinea pig, mouse, rabbit | -- | Hypoactivity | Slow, deep respira- tion | Paulet, 1962 |
| 60 ^c | 3 min | Dog | T-wave alterations in ECG, arrhythmias | Convulsions | -- | Van Stee and Back, 1969 |
| 50 ^a | 2 h | Rat, guinea pig, mouse, rabbit | -- | Initial slight depression | -- | Paulet, 1962 |
| 50 ^c | 40 min | Dog | EKG changes after injec- tion of epinephrine | Convulsions | -- | Van Stee and Back, 1969 |

Table 2 (continued)

| (BrF ₃) Conc., % | Exposure Duration | Animal | Cardiovascular Effects | Central Nervous System Effects | Other Observations | Reference |
|---------------------------------|----------------------|--------------------------------------|--|---|---|-------------------------------|
| 20-42 ^c | 15 min | Monkey | -- | Decrements in avoidance - per formance tests, higher concentrations caused animals to cease performance entirely | -- | Carter et al., 1970 |
| 20-40 ^c | Up to 40 min | Dog | Increased heart rate | -- | -- | Van Stee and Back, 1969 |
| 37 ^b | 7 h | Cat | -- | -- | 1 of 1 died | Graham, 1978 |
| | | Guinea pig | -- | -- | 6 of 6 died | |
| | | Mouse | -- | -- | 8 of 10 died | |
| | | Rat | -- | -- | 4 of 10 died | |
| | | Rabbit | -- | -- | 4 of 4 died | |
| 37 ^b | 7 h | Guinea pig | -- | -- | No deaths | Graham, 1978 |
| 30 ^b | 2 h | Rabbit, guinea pig, rat, mouse | -- | -- | No effect seen | Paulet, 1962 |
| 20 ^b | 2 h | Monkey | -- | -- | Glassy eyes | Graham, 1978 |
| | | Rabbit | -- | -- | Restlessness | |
| | | Guinea pig | -- | -- | Lacrimation | |
| | | Rat | -- | -- | Restlessness | |
| 20 ^b | 2 h | Guinea pig | -- | -- | No signs of toxicity observed | Reinhardt and Reinke, 1972 |
| 20 ^b | 5 min | Dog | Arrhythmias in 8 of 13 after injection of epinephrine | -- | -- | Mullin et al., 1978 |
| 10.5-20 ^c | 15 min | Monkey | -- | No decrements in avoidance - performance tests | -- | Carter et al., 1970 |
| 10-20 ^b | 2 h | Monkey, rabbit, guinea pig | -- | -- | No change in physi- cal appearance or blood chemistry | Reinhardt and Reinke, 1972 |
| 18 ^b | 7 h | Rabbit | -- | -- | 1 of 4 died | Graham, 1978 |
| | | Cat, mouse, guinea pig | -- | -- | No deaths | |
| 15 ^b | 2 h | Monkey | -- | -- | Glassy eyes | Graham, 1978 |
| | | Rabbit, guinea pig, rat | -- | -- | No effects | |

Table 2 (continued)

| CBR ^a Conc., % | Exposure Duration | Animal | Cardiovascular Effects | Central Nervous System Effects | Other Observations | Reference |
|---------------------------|-------------------|--|---|--------------------------------|--------------------|---------------------|
| 15 ^b | 5 min | Dog | Arrhythmias in 2 of 7 after injection of epinephrine | -- | -- | Mullin et al., 1978 |
| 10 ^b | 30 min | Dog | Arrhythmias in 2 of 12 after injection of epinephrine | -- | -- | Mullin et al., 1978 |
| 10 ^b | 5 min | Dog | Arrhythmias in 8 of 69 after injection of epinephrine | -- | -- | Mullin et al., 1978 |
| 9 ^b | 7 h | Cat, mouse, -- rat, rabbit, guinea pig | -- | -- | No effects | Graham, 1978 |
| 7.5 ^b | 60 min | Dog | Arrhythmias in 1 of 12 after injection of epinephrine | -- | -- | Mullin et al., 1978 |
| 7.5 ^b | 30 min | Dog | Arrhythmias in 2 of 12 after injection of epinephrine | -- | -- | Mullin et al., 1978 |
| 7.5 ^b | 5 min | Dog | Arrhythmias in 1 of 18 after injection of epinephrine | -- | -- | Mullin et al., 1978 |
| 5 | 60 min | Dog | No arrhythmias in 12 after injection of epinephrine | -- | -- | Mullin et al., 1978 |
| 5 ^b | 5 min | Dog | No arrhythmias in 16 after injection of epinephrine | -- | -- | Mullin et al., 1978 |
| 0.9-5 ^b | 2 h | Guinea pig | -- | -- | No effects | Graham, 1978. |

^a In air enriched with oxygen.^b In air.^c In oxygen.

TABLE 3

Effects on Animals of Prolonged Exposure to CBrF₃

| CBrF ₃ Conc., % | Exposure Duration | Animal | Effects | Reference |
|-------------------------------|----------------------|--|--|-----------------------------|
| 20-60 ^a | Up to 70 h | Rat (3), guinea pig (3), dog (1), cat (3) | None observed | Scholz and Weigand, 1964 |
| 50 ^b | 2 h/d, 15 d | Mouse (20), rat (10), guinea pig (10) | None observed | Paulet, 1962 |
| 18 ^c | 7 h twice | Cat (1) Guinea pig (5) Rabbit (4) Rat (10) Mouse (10) Dog (1) | None observed 5 died 1 died None observed None observed None observed | Graham, 1978 |
| 9 ^c | 7 h twice | Dog (1) | None observed | Graham, 1978 |
| 8.7 ^c | 7 h twice | Guinea pig (6) | 4 died | Graham, 1978 |
| 5 ^c | 24 h/d, 10 d | Rat (20), guinea pig (20) | No signs of toxicity or blood and cellular changes observed | McHale, 1974 |
| 5 ^a | 23 h/d, 30 d | Rat | No hematologic or gross pathologic changes observed | Griffin et al., 1972 |
| 2.3 ^c | 6 h/d, 5 d/wk, 18 wk | Rat (30), dog (2) | No signs of tox- icity observed, pul- monary congestion | Comstock et al., 1953 |
| 2.8 ^c | 29 d | Monkey | Blood content 100-300 µg/ml | Geller et al., 1981 |

Tinston (1982) reported that CBrF₃ at 42% resulted in gross CNS effects (tremors, ataxia, or loss of righting reflex) in 50% of rats in 10 min.

Four baboons were used in a behavioral study involving a match-to-sample discrimination task, and six cynomolgus monkeys were studied for conditioned emotional response and cardiac arrhythmias (Geller *et al.*, 1981). Each species was exposed continuously to CBrF₃ at 2.8% for 30 d. The monkeys were under severe stress during the study, and two had to be sacrificed before its completion. The baboons served as their own controls; behavioral tests were done before, during, and after the exposure period. Some prolongation of reaction time was found during the exposure period, and it was significant in two of the four animals.

CARDIOVASCULAR EFFECTS

Like many other halogenated hydrocarbons, CBrF₃ sensitizes the heart to the effects of epinephrine. Cardiac arrhythmias and ventricular fibrillation have been produced in animals exposed to CBrF₃ with or without the injection of epinephrine. The 10 min EC₅₀ of CBrF₃ for ventricular tachycardia or arrhythmia in dogs given epinephrine was 20% (Clark and Tinston, 1982).

Anesthetized dogs exposed to CBrF₃ at 80% in oxygen for up to 40 min developed ventricular fibrillation and cardiac arrest after intravenous injection of epinephrine (5-10 µg/kg) (Van Stee and Back, 1969). Monkeys and baboons developed spontaneous arrhythmias within 40 s of exposure to CBrF₃ at 20-90% (Van Stee and Back, 1969). Dogs were not quite as sensitive; arrhythmias began within 2 min of exposure at concentrations of 40% or greater. In another study, however, half the dogs exposed to CBrF₃ at 20% for 5 min and given injections of epinephrine (5 µg/kg) during the last 10 s developed arrhythmias (Clark and Tinston, 1973).

Mullin *et al.* (1978) exposed dogs to CBrF₃ at 5-20% after injection of epinephrine at 8-10 µg/kg. Arrhythmias considered to pose "a serious threat to life" were tabulated. These were defined as multiple consecutive ventricular beats or ventricular fibrillation. None of the dogs exposed to CBrF₃ at 5% had serious arrhythmias. One of 18 at 7.5% and an increasing proportion of dogs at higher concentrations (8 of 13 at 20%) were so affected.

Trochimowicz *et al.* (1976) exposed dogs that had recovered from experimentally induced myocardial infarctions to CBrF₃ at 5, 7.5, and 10% and then gave them intravenous injections of epinephrine. They found no greater potential for cardiac sensitization in dogs that had recovered from myocardial infarction than in normal animals.

CBrF₃ at 10-80% caused a decrease of 10-60 mm Hg in mean arterial blood pressure in dogs; the magnitude of the decrease was generally related to the concentration of the gas (Van Stee and Back,

1969). Some dogs exposed to CBrF_3 also had increases in heart rate at concentrations of 20-30%, and all had increases of 10-15% at concentrations of 40% or greater. Monkeys also exhibited increases in heart rate of 10-15% associated with exposure to CBrF_3 at over 20% during the first minute of exposure and before ventricular premature beats appeared. Back and Van Stee (1979) exposed five dogs to CBrF_3 at 50 and 75%. The mean peak $\text{dp/dt} - \text{p}$ (rate of change of intraventricular pressure) during the CBrF_3 exposures differed significantly ($P < 0.01$) from those measured during before exposure and 10 min after exposure.

EFFECTS OF PROLONGED EXPOSURE

Studies of animals exposed to CBrF_3 for long periods have been limited to investigating gross signs of toxicity. No effects were observed in three rats, three guinea pigs, three cats and one dog exposed at 20-60% for up to 70 h (Scholz and Weigand, 1964) or in 20 mice, 10 rats and 10 guinea pigs exposed at 50% for 2 h/d for 15 d (Paulet, 1962). All five guinea pigs and one of four rabbits died after two 7-h exposures to CBrF_3 at 18% (Haskell Laboratory, 1978). Cats, dogs, rats, and mice were unaffected. Continuous exposure for 10 d at 5% produced no observable signs of toxicity or any histologic or hematologic changes in rats and guinea pigs (McHale, 1974). Similar results were obtained in rats exposed at 5% for 23 h/d for 30 d (Griffin *et al.*, 1972). In rats and dogs exposed at 2.3% for 6 h/d, 5 d/wk, for 18 wk, the only effect seen was some pulmonary congestion (Comstock *et al.*, 1953).

These data on prolonged exposure indicate that a CBrF_3 concentration of 5% in air produces no effect on blood chemistry and does not cause pathologic changes. Specifically, none of these studies found histopathologic damage to CNS or cardiovascular tissue. However, none of them investigated the possibility of functional CNS or cardiovascular changes (as measured by psychomotor or electrophysiologic tests), which acute exposures to CBrF_3 are known to produce. Detailed studies of that kind are needed before the Committee can completely assess the risks of prolonged exposure to CBrF_3 .

CARCINOGENICITY, MUTAGENICITY, AND TERATOGENICITY

No evidence of a carcinogenic potential has been found. However, the longest study conducted was an 18-wk inhalation study (Comstock *et al.*, 1953)

CBrF_3 was tested in Salmonella typhimurium strains TA 1535, TA 1537, TA 1538, TA 98, and TA 100 at up to 40%. The gas was not mutagenic either in the presence or in the absence of a liver microsomal system (Haskell Laboratory, undated).

Groups of 27 pregnant rats were exposed to CBrF_3 at 962 ± 57 , $10,196 \pm 1514$ or $49,505 \pm 4753$ ppm for 6 h/d on days 6-15 of

gestation. No compound-related clinical signs of toxicity or changes in behavior were noted. The outcome of pregnancy -- measured by the number of implantation sites, resorptions, and live fetuses -- was not adversely affected by the exposure. Exposure did not affect fetal development as measured by fetal weight and crown-rump length. Three fetuses were found with malformations; all three were from dams exposed at the intermediate level, but, these effects were not considered compound-related. Under the conditions of this test, CBrF₃ was not embryotoxic or teratogenic (Haskell Laboratory, undated).

PHARMACOKINETICS

Blood concentrations of CBrF₃ in dogs and humans after brief exposure appear to be roughly comparable. In dogs exposed at 5, 7.5, and 10%, arterial and venous concentrations rose rapidly during the first 5 - 10 min of exposure and then fluctuated about a plateau until exposure was stopped after 60 min (Mullin *et al.*, 1978). By 5 min after exposure, blood concentrations had decreased to about one-third of the plateau value in venous blood and one-fourth to one-tenth in arterial blood. The mean concentrations between 20 and 60 min of exposure are shown in Table 4.

Van Stee *et al.* (1971) exposed 30 mice to CBrF₃ at 80% for 5 h/d for 3 consecutive days. The hexabarbitol sleeping times and zoxazolamine paralysis times were not found to be different between CBrF₃-exposed mice and control animals.

Mean venous concentrations in six human volunteers exposed to CBrF₃ at 7% were between 26 and 28 µg/g of blood between 30 min and 3 h after onset of exposure (Harrison *et al.*, 1982). Postexposure blood concentrations were not reported. The concentration in alveolar air decreased rapidly during the first 2 h after cessation of exposure, but measurable amounts were still found after 19 h. Serum bromine, a possible indicator of the breakdown of CBrF₃, was undetectable.

Van Stee and Back (1971) studied tissue concentrations in rats acutely exposed to CBrF₃ at 70-75% in oxygen for 5 min. At the end of the 5-min exposure, the brain concentration was approximately 50% greater than the heart concentration. The heart concentration did not differ significantly from the blood concentration. The postexposure rates of decrease in tissue concentrations of CBrF₃ were approximately equal. Only trace amounts of CBrF₃ were detectable beyond 10 min after exposure.

In the study of Geller *et al.* (1981) on cynomolgus monkeys discussed earlier, the amount of CBrF₃ in venous blood of three monkeys was examined after 29 d of exposure at 2.8%. The concentrations were between 100 and 300 µg/ml in individual animals. No data were given on short exposures. These blood concentrations are at least 10 times those expected from results in dogs and humans after short exposures. Whether the difference is related to species,

TABLE 4

Blood Concentrations of CBrF3 in Dogs at Equilibrium (20-60 Minutes)^a

| <u>Exposure Concentration, %</u> | <u>Mean Arterial Blood Concentration, $\mu\text{g/ml}$</u> | <u>Mean Venous Blood Concentration, $\mu\text{g/ml}$</u> |
|--------------------------------------|---|---|
| 5% | 19.2 | 14.6 |
| 7.5% | 30.6 | 28.4 |
| 10% | 40.2 | 32.1 |

^aData from Mullin et al. (1978).

longer exposure time, or the physical condition of the animals used cannot be determined.

HEALTH EFFECTS OF BROMOTRIFLUOROMETHANE DECOMPOSITION PRODUCTS

The relatively slight acute toxicity of CBrF_3 , compared with that of other halogenated fire-extinguishing agents, and its general effectiveness in fighting some kinds of fires have led to its widespread acceptance. Because of the likelihood of decomposition during use, the toxicity of its decomposition products must also be considered in evaluating its appropriateness as a fire-extinguishing agent.

CBrF_3 begins to decompose on contact with a flame or hot surface at approximately 540°C (Haskell Laboratory, 1978). Decomposition products of CBrF_3 that have been identified include hydrogen fluoride (HF), hydrogen bromide (HBr), bromine gas (Br_2), and carbonyl halides (COF_2 and COBr_2). In one study, rats were exposed for 15 min to the products of CBrF_3 pyrolyzed in a hydrogen-oxygen flame at 800°C (Haun *et al.*, 1969). The concentrations of CBrF_3 before and after ignition of the material were measured, and the difference represented the concentration of pyrolyzed CBrF_3 . When CBrF_3 was originally at 3,400–7,900 ppm (0.34–0.79%), it was found that 49–50% was pyrolyzed. HF was by far the most prevalent decomposition product; HBr and Br_2 were also detected. The rats were observed for 14 d after exposure. The LC_{50} for pyrolyzed CBrF_3 for a 15 min exposure was 2,300 ppm (0.23%). Autopsies showed pulmonary congestion, edema, and hemorrhage, which were of increased severity at the higher concentrations of pyrolysis products. Severe eye and nose irritation occurred in rats exposed at or above the LC_{50} . The toxic effects of pyrolyzed CBrF_3 were attributed to the formation of HF. It was found that pyrolysis of CBrF_3 at 3,920 ppm (0.39%) resulted in an HF concentration of 2,280 ppm (0.23%), which is similar to the LC_{50} for HF and for pyrolyzed CBrF_3 (Haun *et al.*, 1969).

The approximate lethal concentration of CBrF_3 in rats for a 15-min exposure was found to be 14,000 ppm (1.4%) for pyrolysis in an iron tube at 800°C and 17,000 ppm (1.7%) for pyrolysis in an Inconel tube at $1,090^\circ\text{C}$ (Chambers *et al.*, 1950; Haun *et al.*, 1969).

McHale (1974) measured the rate of formation of pyrolysis products. Liquid- and solid-fuel fires were set in a 3.75-in-diameter pan in a 16-ft³ chamber. About 3% CBrF_3 was needed to extinguish the fire, and it was found that HF was formed at the rate of 30 ppm/s. The author stated that that was equivalent to a 1-ft-diameter fire in a 1,000-ft³ enclosure producing HF at 5 ppm/s of discharge time. To examine the effects of CBrF_3 under fire conditions, male rats were exposed for 1 h to room air, to the vapors from a 30-s acetone fire, or to the vapors produced by extinguishing an acetone fire in 7.5 s with CBrF_3 . The rats were observed for 72 h, and the

only adverse effect seen was labored breathing in the rats exposed to the vapors of the CBrF_3 -extinguished fire (McHale, 1974).

When mice and rats were exposed to the vapors from a gasoline fire extinguished with CBrF_3 in 15-60 s, the highest mortality rate observed was 6% (Comstock and Oberst, 1953). The concentration of CBrF_3 ranged from 0.18-0.27%, and the temperature in the chamber, from 28 to 51°C. Adverse effects included incoordination, increased respiration, and congestion of the trachea and lungs. The only decomposition products detected were carbonyl halides in trace amounts.

Pyrolysis temperature has been observed to affect the toxicity of CBrF_3 dramatically (Paulet, 1962). CBrF_3 (400,000-800,000 ppm) (40-80%) was heated to 800°C in an iron tube. All rats, mice, and guinea pigs exposed to its pyrolysis products survived after exposure for 30 min. Some animals became prostrate and had labored breathing. When the pyrolysis temperature was raised to 1,000°C, all animals exposed at 10,000 ppm (1%) died, and half those exposed at 5,000 ppm (0.5%) died. Toxic effects included irritation of the eyes, nose, and throat and pulmonary edema.

At high temperatures or when CBrF_3 is used to extinguish large fires in enclosed spaces, HF is the most important toxic decomposition product, because of the amount formed and its inherent toxicity, in comparison with other decomposition products (Vernot, 1967). At the LC_{50} value of pyrolyzed CBrF_3 (2,300 ppm), 2,480 ppm of HF were formed (Vernot, 1967).

When fires are extinguished rapidly and completely, as is the case when discharge time is short and CBrF_3 concentration is 6-7%, the formation of decomposition products is so small as to be of no concern with regard to toxicity and corrosivity. Contact time with flame and hot surfaces appears to be the critical factor.

The DuPont Company has reported that under most fire situations where CBrF_3 is used in automatic protection systems, the HF concentration is usually less than 20 ppm -- often barely detectable to the nose. However, severe fire tests indicate that larger amounts of HF (200-300 ppm) and HBr (40-50 ppm) are produced when CBrF_3 decomposes in the extinguishing of a large, hot fire (DuPont, undated). Such concentrations are noxious and irritating and may be harmful if exposure is prolonged. Even in very low concentrations, however, these gases have a characteristic sharp, acrid odor, which constitutes a built-in warning system.

The U.S. Coast Guard (1972) conducted several fire tests to determine the efficacy of CBrF_3 and the production of its decomposition products. Its conclusion was that, in most cases when the CBrF_3 concentration was above 5% and discharge time was 10 s or less, HF and HBr were produced at below 5 ppm and 1 ppm, respectively, and that the discharge time was very important (the smaller the

discharge time, the smaller the amounts of decomposition product). By comparison, the emergency and continuous exposure limits for HF recommended by the National Research Council (1971b) were as follows: 10 min, 20 ppm; 30 min, 10 ppm; 60 min, 8 ppm; 24 h, 2 ppm; and 90 d, 1 ppm.

A comparison of the acute toxicity of nondecomposed CBrF_3 vapor with that of decomposed vapor shows that, in a fire, the toxicity of CBrF_3 can be greatly increased, depending primarily on the temperature of the fire. Whereas the approximate lethal concentration of nondecomposed CBrF_3 is greater than 80% in rats and mice, during pyrolysis the approximate lethal concentration has been reported to be as low as 1%. However, wide variations in the lethal concentration of CBrF_3 from pyrolysis have been reported. The differences are due to the lack of uniformity of method, and to differences in temperature, type of fuel burned, and oxygen availability. All can produce differences in the quantities and types of pyrolysis products. Therefore it is difficult to make valid comparisons from these studies.

INHALATION EXPOSURE LIMITS

The American Conference of Governmental Industrial Hygienists (1980, 1983) has recommended a threshold limit value (TLV) of 1,000 ppm (0.1%) for CBrF_3 as a time-weighted average (TLV-TWA) concentration for an 8-h workday and a 40-h workweek. That value was selected because "it represents the maximal limit hygienically desirable for any contaminant." A 15-min short-term exposure limit (STEL) of 1,200 ppm was also recommended by the ACGIH. The Occupational Safety and Health Administration (1983) proposed 1,000 ppm as the standard for an 8-h time-weighted average concentration.

COMMITTEE RECOMMENDATIONS

The Committee on Toxicology of the National Research Council has responded to prior requests from its sponsoring agencies to review the literature concerning CBrF_3 . Inhalation exposure limits were recommended in 1967, 1973, and 1979.

In 1967, the Committee evaluated the toxicity of CBrF_3 for the National Aeronautics and Space Administration (NASA). On the basis of human and animal toxicity data, the Committee concluded that personnel can be exposed without substantial hazard for a maximum of 5 min to normal air at 1 atm admixed with CBrF_3 at a mean concentration of up to 60,000 ppm (6%) by volume. That conclusion was based on the assumption that the fire would be extinguished promptly by CBrF_3 and that pyrolysis would be minimized.

In 1973, the Navy asked the Committee to recommend 1-, 8-, and 24-h exposure limits for CBrF_3 , because it would be carried on submarines. Because CBrF_3 would not be removed by the air purification system of a submarine, the crew might be exposed

during its entire mission and in the absence of information on the effects of long-term exposure to CBrF_3 , the Committee elected not to recommend maximal exposure limits. The Committee later approved a 10-min exposure limit for CBrF_3 of 70,000 ppm (7%) in shipboard machinery spaces, provided that a ventilation system could begin operating immediately on the release of CBrF_3 at an air-exchange rate of 2-4 min and continue operating for 20 min.

NASA asked the Committee in 1979 to recommend exposure limits for CBrF_3 , which was to be used in the fire-extinguishing systems of the shuttles Orbiter and Spacelab. The Committee (NRC, 1979b) recommended a 1-h EEL of 25,000 ppm (2.5%), on the basis of minor reversible CNS effects in humans exposed at 4.5% for up to 30 min, an absence of effects in humans exposed at 3% for 30 min or less, and an absence of effects in several species of animals exposed at 9% for up to 7 h. (Tables 1 and 2).

Studies on CBrF_3 issued or published since the last report of the Committee on Toxicology (1979b) are compatible with its conclusions on short-term toxic effects. They reinforce the conclusion that, for short-term exposures, the pyrolysis products of CBrF_3 are much more toxic than the parent compound. Intense fires in enclosed spaces could produce concentrations of HF, in particular, that far exceed recommended human exposure limits proposed by the Committee (1971b). Protection against these exposures and rapid exchange of air after fires in enclosed spaces that humans must occupy are needed. The Committee therefore recommends a 1-h EEL of 25,000 ppm (2.5%) and a 30-min EEL of 40,000 ppm (4.0%). Some decrements, such as in reasoning and equilibrium, may be experienced by some persons at these concentrations.

Portable monitoring devices are available for CBrF_3 and HF and should be used before one enters areas where CBr_3 was used for extinguishing fires.

The Committee also recommends a 90-d CEL of 100 ppm. That is based on the study of Comstock et al. (1953), who showed that rats and dogs exposed at 23,000 ppm (vol/vol) for 6 h/d, 5 d/wk, for 18 wk showed no substantial adverse effects. However, no chronic-exposure studies have included carcinogenicity. On the basis of its low biologic reactivity, negative in vitro mutagenicity results, and similarity to other fluorocarbons, it is unlikely to be carcinogenic. The CEL of 100 ppm is in agreement with the CEL established for FC-11, FC-12, FC-113 and FC-114--all closely related to CBrF_3 (NRC, 1984).

The present Committee's recommended EELs and CEL for bromotrifluoromethane and the limits proposed previously are shown below.

| | <u>1967</u> | <u>1973</u> | <u>1979</u> | <u>1984</u> |
|------------|-------------|-------------|-------------|-------------|
| 5-min EEL | 60,000 ppm | -- | -- | -- |
| 10-min EEL | -- | 70,000 ppm | -- | -- |
| 30-min EEL | -- | -- | -- | 40,000 ppm |
| 1-h EEL | -- | -- | 25,000 ppm | 25,000 ppm |
| 90-d CEL | -- | -- | -- | 100 ppm |

REFERENCES

- American Conference of Governmental Industrial Hygienists. 1980. Trifluorobromomethane. Documentation of the Threshold Limit Values. 4th Ed. Cincinnati, Ohio: American Conference of Governmental Hygienists. p. 414
- American Conference of Governmental Industrial Hygienists. 1983. TLVs^R - Threshold Limit Values for Chemical Substances and Physical Agents in the Work Environment with Intended Changes for 1983-1984. Cincinnati, Ohio: American Conference of Governmental Industrial Hygienists. 93 p.
- Back, K. C. and Van Stee, E.W. 1979. Various techniques for evaluating cardiodynamic function using chronically instrumented canine models. *Parmaol. Ther.* 5:103-113.
- Call, D. W. 1973. A study of Halon 1301 (CBrF₃) toxicity under simulated flight conditions. *Aerospace Med.* 44:202-204.
- Carter, V. L., Jr., Back, K. C., and Farrer, D. N. 1970. The effect of bromotrifluoromethane on operant behavior in monkeys. *Toxicol. Appl. Pharmacol.* 17:648-655.
- Chambers, W. H. Krackow, E. H. Comstock, C. C. McGrath, F.P., Goldberg, S.B., Lawson, L. H., and MacNamee, J. K. 1950. An Investigation of the Toxicity of Proposed Fire Extinguishing Fluids. Parts I-III. MDRR No. 23. Army Chemical Center, MD.: Chemical Corps Medical Division. 46 p.
- Clark, D. G. and Tinston, D. J. 1973. Correlation of the cardiac sensitizing potential of halogenated hydrocarbons with their physicochemical properties. *Brit. J. Pharmacol.* 49:355-357.
- Clark, D. G., and Tinston, D. J. 1982. Acute inhalation of some halogenated and non-halogenated hydrogens. *Human Toxicol.* 1:239-247.
- Comstock, C. C., Kerschner, J., and Oberst, F. W. 1953. Toxicology of Inhaled Trifluorobromomethane and Difluorodibromomethane Vapors from Subacute and Chronic Exposures of Rats and Dogs. Report No. 180. Army Chemical Center, MD.: Chemical Corps Medical Laboratories. 19 p.
- Comstock, C.C. and Oberst, F.W. 1953. Comparative inhalation toxicities of four halogenated hydrocarbons to rats and mice in the presence of gasoline fires: Carbon tetrachloride, monochloromonobromomethane, difluorodibromomethane, and trifluoromonobromomethane. *AMA Arch. Ind. Hyg. Occup. Med.* 7:157-167.
- DuPont de Nemours & Co. [no date] DuPont Halon 1301 Fire Extinguisher Technical Bulletin B-29E. Wilmington, Delaware: E.I. duPont deNemours & Co. 12 p.

- Farrier, R. H. 1983. Letter dated May 31 from Director of Occupational and Preventive Medicine Division, U.S. Navy to Committee on Toxicology, National Research Council, Washington, D.C.
- Geller, I., Garcia, C., Gleiser, C., Haines, R. Jr., Hamilton, M., Hartmann, R., Jr., Mendex, V., Samuels, A., San Miquel, M. 1981. Report on Evaluation of the CNS and cardiovascular Effects of Prolonged Exposure to Bromotrifluoromethane (CBrF₃). San Antonio, Texas: Southwest Foundation for Research and Education. 234 p. [Unpublished]
- Griffin, T. B., Byard, J. L., and Coulston, F. 1972. Toxicological responses to halogenated hydrocarbons. In: An Appraisal of Halogenated Fire Extinguishing Agents. Committee on Fire Research and Committee on Toxicology. Washington, D.C. National Academy of Sciences. pp. 136-147.
- Harrison, J. N., Smith, D. J., Strong, R., Scott, M., Davey, M., and Morgan, C. 1982. The use of Halon 1301 for firefighting in confined spaces. J. Soc. Occup. Med. 32: 37-43.
- Haskell Laboratory for Toxicology and Industrial Medicine. 1978. Literature Review on Bromotrifluoromethane. Newark, Delaware: E.I. du Pont de Nemours & Co. 20 pp. [Unpublished]
- Haskell Laboratory for Toxicology and Industrial Medicine. [no date] Unpublished data on mutagenicity and carcinogenicity of bromotrifluoromethane as cited in: Literature Review of Bromotrifluoromethane. Newark, Delaware: E.I. du Pont de Nemours & Co. 13 p. [Unpublished].
- Haun, C. C., Vernot, E. H., Geiger, D. L., and McNerney, J. M. 1969. The inhalation toxicity of pyrolysis products of bromochloromethane (CH₂BrCl) and bromotrifluoromethane (CBrF₃). Am. Ind. Hyg. Assoc. J. 30:551-558.
- Hine, C. H., Elliott, H. W., Kaufman, J. W., Leung, S., and Harrah, M. D. 1968. Clinical toxicologic studies on Freon FE1301. pp. 127-144 in Proceedings of the 4th Annual Conference on Atmospheric Contamination in Confined Spaces, 10-12 September 1968. Report AMRL-TR-68-175. Wright-Patterson Air Force Base, Ohio. [Available from Defense Documentation Center, Alexandria, Va. as AD-855-001].
- McHale, E. T. 1974. Life support without combustion hazards. Fire Technol. 10:15-24.
- Mullin, L. S., Reinhardt, C. F., and Hemingway, R. E. 1978. Cardiac arrhythmias and blood levels associated with inhalation of Halon 1301. Am. Ind. Hyg. Assoc. J. 40:653-658.
- National Academy of Sciences. 1972. Symposium on: An Appraisal of Halogenated Fire Extinguishing Agents. National Academy of Sciences. Washington, D.C. 349 p.

- National Research Council, Ad Hoc Committee on Toxicology. 1964. Basis for Establishing Emergency Inhalation Exposure Limits Applicable to Military and Space Chemicals. Washington, D.C.: National Academy of Sciences. 5 p.
- National Research Council, Committee on Toxicology. 1971a. Basis for Establishing Guide for Short-term Exposures of the Public to Air Pollutants. Washington, D.C.: National Academy of Sciences. 15 p.
- National Research Council, Committee on Toxicology. 1971b. Guides for Short-term Exposures of the Public to Air Pollutants. III. Gaseous Hydrogen Fluoride. Washington, D.C.: National Academy of Sciences. 10 p.
- National Research Council, Committee on Toxicology. 1979a. Criteria for Short-Term Exposures to Air Pollutants. Washington, D.C.: National Academy of Sciences. 15 p.
- National Research Council, Committee on Toxicology. 1979b. Bromotrifluoromethane - A Literature Review. Washington, D.C.: National Academy of Sciences. 16 p.
- National Research Council, Committee on Toxicology. 1984. Emergency and Continuous Exposure Limits for Selected Airborne Contaminants. Vol. 2. Washington, D.C.: National Academy Press. 123 p.
- Occupational Safety and Health Administration. 1983. Toxic and Hazardous Substances. Air Contaminants. 29CFR 1910.1000
- Paulet, G. 1962. Etude toxicologique et physiopathologique du monobromo-trifluoromethane (CF_3Br). [Toxicological and physiopathologic study of monobromo-trifluoromethane (CF_3Br). Arch. Mal. Prof. 23:341-348.
- Reinhardt, C. F. and Reinke, R. E. 1972. Toxicology of halogenated fire extinguishing agents Halon 1301 (bromotrifluoromethane). In: An Appraisal of Halogenated Fire Extinguishing Agents. Committee on Fire Research and Committee on Toxicology. Washington, D. C. National Academy of Sciences pp. 67-78.
- Scholz, J. and Weigand, W. 1964. Toxicological investigation of trifluorobromomethane. Zente. Arbeitsmed. Arbeitsschutz. 14:129-31. (CHEM Abstr. 62:2166h, 1965).
- Stewart, R. D, Newton, P. E., Wu, A., Hake, C. L., and Krivanek, N.D. 1978. Human exposure to Halon 1301. Medical College of Wisconsin, Dept. of Environmental Medicine, Milwaukee, Wisconsin. 46 p. [unpublished]
- Trochimowicz, H. J., Reinhardt, C. F., Mullin, L. S., Azar, A., and Karrh, B. W. 1976. The effect of myocardial infarction on the cardiac sensitization potential of certain halocarbons. J. Occup. Med. 18:26-30.

- United States Coast Guard. 1972. An Investigation into the Effectiveness of Halon 1301 (Bromotrifluoromethane CBrF_3) as an Extinguishing Agent for Shipboard Machinery Space Fires. U. S. Coast Guard, Washington, D. C. Office of Research and Development, Safety Equipment Branch. 85 p.
- Van Stee, E. W. and Back, K. C. 1969. Short-term inhalation exposure to bromotrifluoromethane. *Toxicol. Appl. Pharmacol.* 15:164-174.
- Van Stee, E.W., Back, K.C., and Prynn, R.B. 1970. Alteration of the electroencephalogram during bromotrifluoromethane exposure. *Toxicol. Appl. Pharmacol.* 16:779-785.
- Van Stee, E. W., and Back, K.C. 1971. Brain and Heart Accumulation of Bromotrifluoromethane. AMRL-TR-70-139. Wright-Patterson Air Force Base, Ohio: Aerospace Medical Medical Research Laboratory. 10 p.
- Van Stee, E.W., Murphy, J.P.F., and Back, K.C. 1971. Halogenated hydrocarbons and drug metabolism: The effect of fluorocarbons on hexobarbital sleeping and zoxazolamine paralysis times in mice. P. 71-84. In: Proceedings of the 2nd Annual Conference on Environmental Toxicology Aerospace Medical Division. AMRL-TR-71-120. Wright-Patterson Air Force Base, Ohio: Aerospace Medical Research Laboratory.
- Van Stee, E.W.. 1974. A Review of the Toxicology of Halogenated Fire Extinguishing Agents. AMRL-TR-74-143. Wright-Patterson Air Force Base, Ohio: 79 p. Aerospace Medical Research Laboratory.
- Vernot, E. H. 1967. Inhalation Toxicity and Chemistry of Pyrolysis Products of Bromotrifluoromethane. Pp. 107-117 in Proceedings of Fire Hazards and Extinguishment Conference. Brooks Air Force Base, Texas. Aerospace Medical Division.

END

FILMED

5-85

DTIC